economy

FDA approves argenx's Vyvgart?

PlatformPolymarket Expires2026-05-10 Volume$9,955 Open Interest$289,530
YES
99¢
Implied probability: 99.0%
NO
Implied probability: 0.1%
30-DAY PROBABILITY HISTORY Low 99¢ · High 99¢ · Δ +0.0pp
Advertisement
Kalshi · $25 sign-up bonus Trade event contracts legally in the US. Get $25 free. Kalshi is the CFTC-regulated US exchange for event contracts. Sign up with our link and get $25 in trading credit, no deposit required to claim. This specific contract is on Polymarket (not available to US traders), but Kalshi lists similar events. Open an account →
YES Price
99¢
NO Price
Total Volume
$9,955
Open Interest
$289,530
Expiration
2026-05-10
Days Left
1
About this market

What resolves this contract

As of market creation, the FDA's expected decision date for the specified application is May 10, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for argenx's Vyvgart as a treatment for seronegative generalized myasthenia gravis by May 24, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a s

How to read the price

Prediction market prices are expressed in cents on the dollar. A YES contract trading at 99¢ means the market is pricing in a 99.0% implied probability of the event resolving YES. If resolution comes back YES, the contract pays $1. If NO, it pays $0.

Volume vs. open interest

Total traded volume ($9,955) reflects every buy and sell across the life of this contract. Open interest ($289,530) is the dollar value of positions currently held by traders. Deep liquidity and wide open interest are the two signals that the quoted price is reliable.

Where to trade this market

This contract is listed on Polymarket. PicksByOdds does not accept deposits, execute trades, or offer brokerage. We publish the data; you decide what to do with it.

Advertisement
Related

Markets in the same story

MarketYESVolume
Strait of Hormuz traffic returns to normal by end of May? 27¢ $9,921,739
Will Franco Colapinto be the 2026 F1 Drivers' Champion? $9,918,734
Will the US acquire part of Greenland in 2026? 13¢ $9,779,151
FAQ

Common questions about this market

How is this market resolved?

As of market creation, the FDA's expected decision date for the specified application is May 10, 2026. This market will resolve to "Yes" if the U.S. Food and Drug Administration (FDA) grants full or conditional approval for argenx's Vyvgart as a treatment for seronegative generalized myasthenia gravis by May 24, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No." An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a s

When does this contract expire?

This contract closes on 2026-05-10, 1 day from now. After close, the final outcome is determined per the resolution rules above, and contracts settle at $1 (winning side) or $0 (losing side).

What happens if I buy YES at 99¢?

If the event resolves YES, each YES contract pays $1 , a profit of 1¢ per dollar risked. If it resolves NO, the contract pays $0 and the full 99¢ is lost. Current market price implies a 99.0% probability of YES.

Where is this market listed?

This contract is listed on Polymarket. PicksByOdds aggregates and displays public market data; we do not broker trades or custody funds.

How reliable is the quoted price?

This market has $9,955 in total traded volume and $289,530 in open interest. Deeper liquidity generally means tighter spreads and more reliable implied probabilities. Prices refresh multiple times per day.

Disclaimer: Prediction market data on this page is sourced from public order books. Prices change continuously; figures shown here reflect the last refresh at 2026-05-09. Nothing on this page constitutes investment or betting advice.
Get new posts in your inbox. No spam, unsubscribe anytime.